Feeling privileged to be part of this 👀 Exciting times!
I'd like to share a small update about what we've been doing at @Xaira_Thera . We've been mostly heads down focused on making design to progress internal programs and building out our platform until now. 🧵to follow.
For antibody design to actually add value, it needs to either:
1. dramatically improve the speed and quality of antibodies over traditional discovery pipelines for easy targets
2. unlock therapeutic targets so difficult that they were previously inaccessible to traditional approaches
In this post we provide a tiny preview of two internal programs we designed antibodies to that illustrate our platform meets both of these criteria.
There is of course, a spectrum of targets in between the "easy" and the "undruggable" such as these GPCRs we made VHH and VHVL binders to which we highlight as well:
xaira.com/news/de-novo-d…View quoted post on X
